Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival, using best separation (to the left) and median separation (to the right). Patients were divided based on level of expression into one of the two groups "low" or "high". Below each Kaplan-Meier plot, corresponding expression cutoff, 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For melanoma and glioma, 3-year survival is shown. The survival analysis is described in Assays & Annotation.

The tabs at the top of the survival analysis section can be used to switch between the different cancer subtypes.

Best separation

Median separation

Expression cutoff

5.7 FPKM

5.7 FPKM

5-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

96%

96%

5-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

The Scatter Survival plot shows the clinical status for all individuals in the patient cohort, based on the same data as in the Kaplan-Meier plots. Living patients are shown in blue and deceased patients in red. The x-axis shows the expression levels (FPKM) of the investigated gene at the time of diagnosis and the y-axis shows the number of years of survival (living years) after the diagnosis.

Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or several category buttons to the left. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be changed to "x linear" by clicking on the "x log" button on the left. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

Stage:

TCGA RNA samplesi

RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average FPKM

5.7

Number of samples

134

Samples

Sample

Description

FPKM

TCGA-2X-A9D5-01A

49 years, male, white, stage:i

8.9

TCGA-2G-AAH0-01A

30 years, male, white, stage:is

8.7

TCGA-2G-AAH8-01A

45 years, male, white, stage:iiic

8.5

TCGA-W4-A7U2-01A

26 years, male, white

8.4

TCGA-VF-A8AC-01A

29 years, male, white, stage:ia

8.4

TCGA-ZM-AA0B-01A

32 years, male, white, stage:ia

8.3

TCGA-4K-AA1I-01A

26 years, male, white, stage:ia

8.2

TCGA-2G-AAF4-01A

30 years, male, white, stage:i

8.1

TCGA-2G-AAF1-01A

28 years, male, asian, stage:is

8.0

TCGA-2G-AAEW-01A

31 years, male, white, stage:is

8.0

TCGA-XY-A8S2-01A

67 years, male, white, stage:i

7.9

TCGA-XE-AAO4-01A

40 years, male, white, stage:ia

7.9

TCGA-S6-A8JX-01A

27 years, male, white, stage:ib

7.9

TCGA-YU-A90Q-01A

21 years, male, stage:ib

7.9

TCGA-SO-A8JP-01A

29 years, male, white, stage:i

7.9

TCGA-VF-A8A9-01A

31 years, male, white, stage:ia

7.9

TCGA-SB-A6J6-01A

22 years, male, white, stage:ia

7.8

TCGA-2G-AAG0-01A

23 years, male, white, stage:is

7.7

TCGA-XE-AANJ-01A

39 years, male, white, stage:is

7.7

TCGA-XE-A8H5-01A

29 years, male, stage:is

7.7

TCGA-XE-AAO6-01A

47 years, male, white, stage:ia

7.7

TCGA-XE-AAO3-01A

33 years, male, asian, stage:i

7.7

TCGA-XE-AANV-01A

52 years, male, stage:ib

7.6

TCGA-2G-AAFH-01A

38 years, male, white, stage:iib

7.5

TCGA-S6-A8JY-01A

27 years, male, white, stage:is

7.4

TCGA-ZM-AA0D-01A

34 years, male, white, stage:ia

7.4

TCGA-S6-A8JW-01A

37 years, male, white, stage:is

7.4

TCGA-ZM-AA0N-01A

44 years, male, white, stage:ib

7.3

TCGA-SB-A76C-01A

38 years, male, white

7.1

TCGA-4K-AA1G-01A

34 years, male, white, stage:is

7.1

TCGA-XE-A8H4-01A

23 years, male, white, stage:ia

7.1

TCGA-2G-AAHA-01A

48 years, male, white, stage:ib

7.0

TCGA-2G-AAHT-01A

32 years, male, white, stage:is

6.9

TCGA-2G-AAH3-01A

20 years, male, white, stage:i

6.9

TCGA-2G-AAFG-01A

30 years, male, white, stage:is

6.9

TCGA-2G-AAHC-01A

33 years, male, white, stage:is

6.8

TCGA-VF-A8AD-01A

36 years, male, white, stage:ib

6.8

TCGA-2G-AAFI-01A

41 years, male, white, stage:ib

6.7

TCGA-YU-A912-01A

34 years, male, black or african american, stage:iiic

6.6

TCGA-2G-AAGO-01A

41 years, male, white, stage:is

6.6

TCGA-XE-AAOF-01A

50 years, male, asian, stage:ia

6.6

TCGA-WZ-A8D5-01A

38 years, male, white

6.6

TCGA-2G-AAKL-01A

26 years, male, white, stage:ii

6.5

TCGA-2G-AAGE-01A

21 years, male, white, stage:is

6.5

TCGA-2G-AAGY-01A

28 years, male, white, stage:is

6.3

TCGA-2G-AAEX-01A

38 years, male, white, stage:is

6.3

TCGA-2G-AAG7-01A

33 years, male, white, stage:is

6.2

TCGA-XE-AANR-01A

24 years, male, white, stage:i

6.2

TCGA-XE-AAOL-01A

38 years, male, black or african american, stage:i

6.2

TCGA-WZ-A7V3-01A

20 years, male, white, stage:i

6.2

TCGA-2G-AAFY-01A

24 years, male, white, stage:iia

6.1

TCGA-YU-A90W-01A

45 years, male, white, stage:ia

6.1

TCGA-2G-AAFE-01A

37 years, male, white, stage:iia

6.0

TCGA-YU-A90Y-01A

23 years, male, black or african american, stage:iiic

6.0

TCGA-VF-A8AA-01A

51 years, male, white, stage:i

6.0

TCGA-4K-AAAL-01A

31 years, male, white, stage:is

6.0

TCGA-2G-AAHG-01A

25 years, male, white, stage:i

6.0

TCGA-XE-A9SE-01A

35 years, male, white, stage:ia

5.9

TCGA-XY-A8S3-01B

24 years, male, white, stage:is

5.9

TCGA-ZM-AA0H-01A

50 years, male, white, stage:is

5.9

TCGA-XE-AAOD-01A

39 years, male, white, stage:ib

5.9

TCGA-2G-AAFV-01A

31 years, male, white, stage:is

5.9

TCGA-WZ-A7V5-01A

27 years, male, white, stage:i

5.9

TCGA-2G-AAF6-01A

28 years, male, white, stage:is

5.9

TCGA-XY-A89B-01A

35 years, male, white, stage:ia

5.8

TCGA-2X-A9D6-01A

42 years, male, white, stage:i

5.8

TCGA-2G-AAKM-01A

14 years, male, white, stage:ii

5.8

TCGA-2G-AALP-01A

43 years, male, white, stage:iiib

5.7

TCGA-ZM-AA0E-01A

39 years, male, white, stage:ia

5.7

TCGA-XE-A8H1-01A

24 years, male, white, stage:is

5.7

TCGA-WZ-A7V4-01A

28 years, male, white, stage:i

5.6

TCGA-2G-AAGJ-01A

28 years, male, black or african american, stage:ia

5.6

TCGA-SN-A6IS-01A

26 years, male, white, stage:is

5.6

TCGA-2G-AAGN-01A

41 years, male, white, stage:iiib

5.5

TCGA-ZM-AA0F-01A

35 years, male, white, stage:ia

5.5

TCGA-2G-AAFN-01A

26 years, male, white, stage:iiib

5.5

TCGA-XY-A9T9-01A

37 years, male, white, stage:is

5.5

TCGA-W4-A7U4-01A

23 years, male, white

5.4

TCGA-ZM-AA06-01A

45 years, male, white, stage:ib

5.3

TCGA-2G-AAF8-01A

33 years, male, white, stage:ia

5.3

TCGA-2G-AAGS-01A

39 years, male, white, stage:iiib

5.3

TCGA-2G-AAGW-01A

38 years, male, white, stage:is

5.3

TCGA-2G-AAKG-01A

22 years, male, white, stage:i

5.3

TCGA-VF-A8AE-01A

39 years, male, white, stage:ia

5.3

TCGA-VF-A8A8-01A

18 years, male, white, stage:ia

5.2

TCGA-SN-A84Y-01A

18 years, male, white, stage:is

5.2

TCGA-2G-AAG9-01A

25 years, male, white, stage:iiib

5.2

TCGA-2G-AAGC-01A

28 years, male, white, stage:is

5.1

TCGA-2G-AAGA-01A

38 years, male, white, stage:iia

5.1

TCGA-2G-AAG8-01A

21 years, male, white, stage:ib

5.1

TCGA-2G-AAGK-01A

20 years, male, white, stage:is

5.0

TCGA-2G-AAGI-01A

33 years, male, white, stage:is

5.0

TCGA-2G-AAL7-01A

32 years, male, white, stage:is

4.9

TCGA-2G-AAGM-01A

51 years, male, white, stage:is

4.7

TCGA-4K-AA1H-01A

26 years, male, white, stage:ia

4.6

TCGA-XE-AAOJ-01A

24 years, male, white, stage:is

4.6

TCGA-YU-A90P-01A

25 years, male, white, stage:ia

4.5

TCGA-2G-AAL5-01A

31 years, male, white, stage:i

4.5

TCGA-2G-AAFJ-01A

23 years, male, asian

4.4

TCGA-2G-AAFZ-01A

32 years, male, white, stage:iii

4.4

TCGA-YU-A94I-01A

66 years, male, stage:ia

4.4

TCGA-2G-AAGP-01A

33 years, male, white, stage:iia

4.4

TCGA-2G-AAGF-01A

28 years, male, white, stage:is

4.4

TCGA-YU-A94D-01A

28 years, male, stage:iiib

4.3

TCGA-2G-AAGX-01A

22 years, male, white, stage:ia

4.3

TCGA-XE-AAOC-01A

31 years, male, white, stage:ia

4.2

TCGA-2G-AAKH-01A

19 years, male, white, stage:ii

4.2

TCGA-X3-A8G4-01A

33 years, male, white, stage:is

4.2

TCGA-2G-AAHL-01A

26 years, male, white, stage:i

4.1

TCGA-2G-AAH2-01A

20 years, male, white, stage:is

4.1

TCGA-2G-AAHN-01A

32 years, male, white, stage:i

4.1

TCGA-YU-AA61-01A

29 years, male, white, stage:is

4.1

TCGA-VF-A8AB-01A

31 years, male, black or african american, stage:ia

4.0

TCGA-YU-A90S-01A

26 years, male, white, stage:ia

4.0

TCGA-2G-AAFO-01A

33 years, male, white, stage:iia

4.0

TCGA-2G-AAGG-01A

20 years, male, white, stage:iiic

4.0

TCGA-2G-AAH4-01A

34 years, male, white, stage:ii

3.9

TCGA-2G-AAG5-01A

36 years, male, white, stage:is

3.9

TCGA-2G-AAHP-01A

31 years, male, white, stage:is

3.8

TCGA-2G-AAG6-01A

24 years, male, white, stage:is

3.7

TCGA-YU-AA4L-01A

27 years, male, black or african american, stage:iiic

3.7

TCGA-2G-AAKD-01A

18 years, male, white, stage:iii

3.7

TCGA-2G-AAGZ-01A

27 years, male, white, stage:iiia

3.7

TCGA-SN-A84W-01A

30 years, male, white, stage:is

3.6

TCGA-XE-AAOB-01A

27 years, male, white, stage:is

3.6

TCGA-2G-AAFL-01A

35 years, male, white, stage:ib

3.6

TCGA-2G-AAGV-01A

23 years, male, white

3.5

TCGA-2G-AAG3-01A

53 years, male, white, stage:is

3.5

TCGA-W4-A7U3-01A

26 years, male, white

3.4

TCGA-ZM-AA05-01A

36 years, male, white, stage:iic

3.4

TCGA-2G-AAFM-01A

31 years, male, white, stage:iia

3.3

TCGA-2G-AAGT-01A

30 years, male, white, stage:is

3.2

TCGA-SN-A84X-01A

21 years, male, white, stage:is

3.1

TCGA-XE-AANI-01A

37 years, male, white, stage:is

3.0

Show all

TESTIS CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

Antibody stainingi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival, using best separation (to the left) and median separation (to the right). Patients were divided based on level of expression into one of the two groups "low" or "high". Below each Kaplan-Meier plot, corresponding expression cutoff, 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For melanoma and glioma, 3-year survival is shown. The survival analysis is described in Assays & Annotation.

The tabs at the top of the survival analysis section can be used to switch between the different cancer subtypes.